10-Q · May 19, 2026
Akari Therapeutics' Q1 2026 results reflect a significant increase in operational losses, primarily due to non-cash impairment charges. With $2.8 million in cash and accumulated deficits approaching $279 million, the…
Earnings analysis · 10-Q
AKTX earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The provided 10-Q extract contains no reported revenue, margin, EPS, cash-flow, balance-sheet, or segment figures, preventing a period-over-period operating trend analysis. The principal disclosed development is that…
Read full summary
The provided 10-Q extract contains no reported revenue, margin, EPS, cash-flow, balance-sheet, or segment figures, preventing a period-over-period operating trend analysis. The principal disclosed development is that remediation efforts were implemented, but disclosure controls remained ineffective as of June 30, 2026 pending testing. Risk remains elevated because approximately $30.3 million of IPR&D is subject to potential impairment and the company has relied on $8.3 million and $5.5 million capital raises for funding.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Control remediation implemented
Management states that remediation efforts for the previously identified control deficiencies have already been implemented as of June 30, 2026, subject to testing over a sufficient period.
-
$30.3M development-asset base
The company reported approximately $30.3 million of IPR&D as of June 30, 2026, principally related to AKTX-101 and its ADC Platform, supporting the value of its development portfolio.
What to watch
-
Material control weaknesses persist
Disclosure controls and procedures were still not effective at a reasonable assurance level as of June 30, 2026, due to previously identified material weaknesses involving QuickBooks IT/general controls and purchase-to-pay controls.
-
IPR&D impairment exposure
Approximately $30.3 million of IPR&D remains exposed to future impairment. The filing identifies adverse clinical, regulatory, competitive, pricing and financing-market developments as potential triggers for significant impairment charges.
-
Ongoing financing dependence
The company raised $8.3 million in Q2 2026 after a prior $5.5 million capital offering, highlighting continued dependence on external financing; repeated equity financing may create dilution and does not establish recurring operating cash flow.
Management's outlook
No quantitative revenue or EPS outlook is provided in the filing extract; no explicit guidance was disclosed.
Earlier filings 4
10-K · March 30, 2026
Akari Therapeutics positions itself as an ADC-focused oncology company centered on a novel spliceosome-targeting payload (PH1) and is advancing lead ADC AKTX-101 toward IND-enabling studies with a goal of a…
10-K · March 29, 2024
Akari is a clinical-stage biotech focused on nomacopan (a dual C5 and LTB4 inhibitor) with multiple orphan/fast-track designations and ongoing pediatric Phase 3 work in HSCT‑TMA. The 10‑K discloses a near‑term strategic…
10-Q · August 12, 2015
Celsus reported a narrower operating loss in Q2 2015 of $1,456k versus $2,330k in Q2 2014, driven largely by a sharp reduction in R&D spend after suspension of its MRX‑6 program. Cash fell to $2,718k at June 30, 2015…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.